MLA 0.00% 8.5¢ medical australia limited

Good Quest.J1, when I look at the last 3 months MD is a minor...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,883 Posts.
    lightbulb Created with Sketch. 122
    Good Quest.J1, when I look at the last 3 months MD is a minor holder, my personal belief the fund he and wife have will sit with thier investment..I have spoken to Mark fairly often over the last 12 months and he was always on the front foot re.. MLA he loved it and said to me we want all of Medivet ltd. and Medivet U.S but its to complicated to take the 39.5% at this point. I Did not ring him today because i am sure there would be a standard responce from the ans. ser. .. But i will in the next week he will hold his chair for some time yet. I need to know his thoughts as others have said he was the instigator of this stem cell division, and the only thing that concerns me is ...Did he want to leave?. There may be other reasons.. Which may not surface even very personal reasons so how do we explain to holders with out the world knowing intimate details ... some believe shareholders need to know why the MD steps aside(my point of view is somethings need to be kept in house ) not just a matter of seeking "other interests " Im sure Mark has a different slant on that exit, and i will find out unless its personal.. .On another note i wont be selling my lot collected over many years as the technolgy is why I first bought in , Mark was the bonus .... Cheers holders Vin P.s .. At this Point i see some 200k+ wanting to sell under 40.c A reaction to the the director stepping down no doubt that will be snapped up when that increases a bit ...
 
watchlist Created with Sketch. Add MLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.